Helius Therapeutics is a medicinal cannabis company that has become the first in New Zealand to be authorized by the local medicinal cannabis agency to cultivate and extract the active ingredients of cannabis.
Helius Therapeutics has once again achieved first place, marking an important milestone in our industry. New Zealand will soon be able to fully cultivate and produce medicinal cannabis products. This is exciting news for local patients who seek to legally access high-quality and cost-effective products," said Carmen Doran, CEO of Helius Therapeutics.
The latest verified active ingredient was developed at the Helius manufacturing site in East Auckland. The active compound in cannabis plants - cannabidiol - was extracted from plants grown in Puro, New Zealand's largest and only certified organic medicinal cannabis cultivation.
Earlier this year, Helius signed a five-year supply agreement worth millions of dollars with Puro, headquartered in the South Island. In April, regulatory authorities renewed and expanded Helius' license, allowing them to produce active ingredients on-site using raw cannabis material.
CBD extract manufactured in New Zealand will first be used for medicinal purposes by patients in the country, with other products being exported worldwide. Helius is the first medicinal cannabis company in the country to obtain a GMP manufacturing license. Every general practitioner in New Zealand is authorized to prescribe medicinal cannabis to their patients, and since October of last year, domestically manufactured products have been using imported active ingredients.
An increasing number of New Zealanders are obtaining prescriptions from doctors for medicinal cannabis products made in New Zealand. However, the country's medicinal cannabis program is also committed to developing and testing locally grown and locally manufactured products," said Ms. Doran.
Earlier this month, Helius attended the largest GP CME conference in New Zealand, held in Christchurch. Many doctors are now hopeful that they will be able to prescribe 100% New Zealand medicinal cannabis for their patients.
Excitingly, New Zealand is getting closer to providing 100% locally-grown cannabis medicine to patients in the country. Bringing the supply chain home will also contribute towards achieving the ultimate goals of affordability and accessibility for the medicinal cannabis program, she stated.
According to Carmen Doran, the international mining market is heating up due to competition for producing the best products for European consumers. "New Zealand's GMP certification is recognized throughout Europe and many other countries, providing significant opportunities for New Zealand companies like ours. New Zealand is an ideal international brand with an environmentally friendly and green image, which will help ensure medicinal cannabis becomes a major source of export revenue in the coming decades," says Doran.
Statement:
This article is compiled from third-party information and is intended solely for industry exchange and learning.
This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the authenticity or accuracy of the article's content. The translation of this article is only intended for communication and research within the industry.
Due to limitations in translation proficiency, this article may not express the exact same meaning as the original. Please refer to the original article for accuracy.
In regards to all domestic, Hong Kong, Macau, Taiwan, and foreign related statements and positions, 2FIRSTS maintains complete alignment with the Chinese government.
The copyright of compiled information belongs to the original media and author. If there is any infringement, please contact us to request deletion.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
